LOS ANGELES, Sept. 1 /PRNewswire/ -- SIDMAP, a drug development and drug testing company, today announced the launch of its metabolic profiling services designed to help pharmaceutical companies and biomedical researchers accelerate the drug development and testing process. SIDMAP's patent-pending technology uses smartly labeled metabolic substrate molecules (tracers) to track disease-characteristic metabolic pathways and acquire detailed understanding of human diseases and drug effects at the nano-scale level. By analyzing this data, SIDMAP physicians can provide pharmaceutical companies and biomedical researchers with answers to questions that are crucial in the processes of developing therapeutic drugs.
"SIDMAP provides unique information on the cellular metabolic network, which is critically important to the decision-making processes in drug research and development," said Dr. Laszlo Boros, SIDMAP's co-founder and Chief Scientific Advisor. "Our goal is to help pharmaceutical companies and biomedical researchers shorten the time from discovery to FDA approval using the knowledge gained from a SIDMAP test."
The technology was developed at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center ("LA BioMed") by Dr. Boros and SIDMAP co-founder and Senior Scientific Advisor, Dr. Paul Lee. Dr. Boros is currently an Associate Professor of Pediatrics at UCLA and the Co-Director of the Stable Isotope Research Laboratory at LA BioMed. Dr. Lee is a Professor of Pediatrics at UCLA, the Co-Director of the Stable Isotope Research Laboratory, Vice Chair for Research in the Department of Pediatrics, and a principal investigator as well as the acting Division Chief in the Division of Pediatric Endocrinology at Harbor-UCLA Medical Center. SIDMAP recently executed an exclusive license agreement with LA Biomed -- details and financial terms were not disclosed.
"We are excited about the deal we have signed with SIDMAP," said Kenneth P. Trevett, President and CEO of LA BioMed. "The non-physician owners of the company bring a unique blend of licensing, brand marketing, and healthcare experience. We look forward to collaborating with this new and dynamic company and believe the technology has tremendous applications for the future."
"Metabolomics (analyzing small metabolites in living organisms) has become essential to understanding disease beyond the revelations provided by genomics and proteomics," said David Manheim, SIDMAP's Vice President of Business and Legal Affairs. "Many pharmaceutical companies are recognizing that the best way to contain the rising costs of new drug development is to forge unique strategic alliances to stimulate innovation and maintain growth. The right technology can transform a struggling R&D pipeline into a new revenue stream."
SIDMAP utilizes non-invasive, disease-specific, and cost-effective procedures to accelerate the critical steps in pre-clinical drug candidate selection and testing. While genomics and proteomics may reliably predict disease mechanisms and drug effects, SIDMAP offers accurate and rapid confirmation and refutation of these predictions.
Drs. Lee and Boros have already utilized some of SIDMAP's technology in consulting roles with several major pharmaceutical companies. SIDMAP technology has helped these companies gain significantly greater insight into drug compounds currently in development and up for FDA approval. The data produced by SIDMAP has saved these companies considerable time and resources in their effort to bring pharmaceutical products to market.
More information about SIDMAP is available at the company's website, http://www.sidmap.com/